HIV Drugs Global Market Report 2021: COVID 19 Implications And Growth To 2030 The Business Research Company’s HIV Drugs Global Market Report 2021: COVID-19 Implications And Growth to 2030 LONDON, GREATER LONDON, UK, February 8, 2021 /EINPresswire.com/ -- New year, new updates! Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports Among HIV drugs market trends, the antiretroviral drugs market is increasingly implementing multi-class combination products for treatment of anti-retroviral therapy. Combination drugs combine multiple medications into one drug form. Example for multiclass combination drugs or single-tablet regimens (STRs), include both NRTIs and NNRTIs: doravirine, lamivudine, and tenofovir disoproxil fumarate (Delstrigo). Based on drug class, drugs are segmented into integrase inhibitors, protease inhibitors, multi-class combination products, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and others. According to WHO, around 690,000 people died from HIV in 2019. Many companies are focusing on developing breakthrough products for the treatment through antiretroviral drugs in order to maintain their competitive advantage and penetrate new regional markets.